Merck's Oral PCSK9 Inhibitor Could Pose A Future Threat After Early Trial Success

 
• By Jessica Merrill

MK-0616 – administered orally – reduced LDL cholesterol in patients in two early clinical trials presented at the American Heart Association Scientific Sessions.

pills versus injections
Merck's oral PCSK9 blocker shows similar efficacy to injections • Source: Alamy

More from Cardiovascular

More from Therapy Areas